Donate

Publication

Machine learning within the Parkinson’s progression markers initiative: Review of the current state of affairs

Citation:
Frontiers in Aging Neuroscience, February 13, 2023
Authored By:
Raphael T. Gerraty, Allison Provost, Lin Li, Erin Wagner, Magali Haas and Lee Lancashire
Abstract:
The Parkinson’s Progression Markers Initiative (PPMI) has collected more than a decade’s worth of longitudinal and multi-modal data from patients, healthy controls, and at-risk individuals, including imaging, clinical, cognitive, and ‘omics’ biospecimens. Such a rich dataset presents unprecedented opportunities for biomarker discovery, patient subtyping, and prognostic prediction, but it also poses challenges that may require the development of novel methodological approaches to solve. In this review, we provide an overview of the application of machine learning methods to analyzing data from the PPMI cohort. We find that there is significant variability in the types of data, models, and validation procedures used across studies, and that much of what makes the PPMI data set unique (multi-modal and longitudinal observations) remains underutilized in most machine learning studies. We review each of these dimensions in detail and provide recommendations for future machine learning work using data from the PPMI cohort.
Published in:
Frontiers in Aging Neuroscience
Frontiers
View article

More Publications

April 18, 2024

Nature Genetics

Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disorder

View
March 5, 2024

Translational Psychiatry

Potential causal association between gut microbiome and posttraumatic stress disorder

View
January 29, 2024

Scientific Reports

Differential recruitment of brain circuits during fear extinction in non-stressed compared to stress resilient animals

View
December 29, 2023

Journal of Law and the Biosciences

Defusing the legal and ethical minefield of epigenetic applications in the military, defense, and security context

View
August 1, 2023

Journal of Psychopharmacology

Improving Translational Relevance in Preclinical Psychopharmacology (iTRIPP)

View
July 29, 2023

Frontiers in Neurology

Models and methods: a perspective of the impact of six IMI translational data-centric initiatives for Alzheimer’s disease and other neuropsychiatric disorders

View
View All

Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.

Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.

©2023 Cohen Veterans Bioscience |  Privacy Policy | Terms of Use

Newsletter